Advertisement
DHR or RGEN or RVTY
Which Stock Would AI Choose? Danaher (DHR) vs. Repligen (RGEN) vs. Revvity (RVTY) Stock Comparison
Key Takeaways
- DHR, RGEN, and RVTY operate in overlapping life sciences and bioprocessing sectors, exposing them to similar demand from pharmaceutical and biotech clients.
- Recent market activity shows varied price responses tied to broader healthcare spending trends and supply-chain stabilization.
- DHR offers diversified exposure across diagnostics and life sciences, providing relative stability compared with more specialized peers.
- RGEN focuses on bioprocessing tools, with performance sensitive to biologics manufacturing volumes.
- RVTY emphasizes diagnostics and reagents, facing valuation sensitivity to clinical testing demand and regulatory updates.
- Relative momentum and sector positioning create distinct risk-reward profiles for growth-oriented versus defensive investors.
Introduction
Investors and traders evaluating opportunities in the life sciences equipment and services space often compare DHR, RGEN, and RVTY because these companies share exposure to pharmaceutical research, biomanufacturing, and diagnostics. The comparison is particularly relevant for those seeking to understand relative performance within a sector influenced by healthcare capital expenditure, regulatory developments, and technological adoption in biologics production. Market participants monitoring portfolio diversification or sector rotation may find the analysis useful for assessing how each stock’s business model responds to current economic and industry conditions.
DHR Overview and Recent Performance
Danaher Corporation provides a broad portfolio of life sciences, diagnostics, and environmental solutions. In recent weeks, DHR stock has reflected measured responses to steady demand for its instrumentation and consumables amid ongoing pharmaceutical R&D activity. Market sentiment has been supported by consistent execution across segments and gradual supply-chain normalization. Broader healthcare spending patterns and client capital budgets have influenced trading ranges, with the stock demonstrating resilience relative to more narrowly focused peers during periods of sector volatility.
RGEN Overview and Recent Performance
Repligen Corporation specializes in bioprocessing products used in the manufacture of biologics. Recent market activity for RGEN has been shaped by fluctuations in biologics production volumes and customer inventory management. Sentiment has responded to industry-wide capacity expansions and contract manufacturing trends. The stock has shown sensitivity to updates on client pipelines and manufacturing utilization rates, resulting in performance that tracks closely with bioprocessing demand cycles.
RVTY Overview and Recent Performance
Revvity, Inc. delivers reagents, instruments, and services primarily for diagnostics and life sciences research. In recent weeks, RVTY has navigated shifts in clinical testing volumes and research funding. Performance has been influenced by regulatory pathways for new assays and adoption of advanced diagnostic platforms. Market positioning reflects exposure to both routine testing and specialized research applications, contributing to price behavior that balances defensive characteristics with growth tied to innovation cycles.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots drawn from hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this section. Bots exhibit wide variation in trading styles, strategies, timeframes, performance statistics, and ticker coverage, enabling users to explore options suited to different risk tolerances and objectives. Historical win rates, drawdown metrics, and return ranges provide quantitative context for evaluation. For further details on currently trending options, visit Trending AI Robots.
Head-to-Head Comparison
DHR maintains a diversified business model spanning multiple end markets, offering greater resilience to single-segment slowdowns compared with RGEN’s concentrated bioprocessing focus or RVTY’s diagnostics emphasis. Growth drivers differ: DHR benefits from broad instrumentation demand, while RGEN tracks biologics manufacturing expansion and RVTY responds to diagnostic assay adoption. Recent momentum has varied with each company’s exposure to capital spending cycles. Risk factors include RGEN’s higher sensitivity to production volume swings, RVTY’s regulatory and reimbursement dependencies, and DHR’s scale-related integration challenges. Valuation sensitivity appears highest for growth-oriented names during shifts in interest-rate expectations, while sector sentiment remains broadly supportive of life-sciences infrastructure spending.
Tickeron AI Verdict
Based on observable trend consistency, relative stability across diversified segments, and positioning amid steady healthcare demand, Tickeron’s AI would currently assign a modestly higher probability of favorable risk-adjusted characteristics to DHR over the more specialized profiles of RGEN and RVTY. This assessment rests on comparative resilience in recent market activity rather than any guarantee of future results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green whileRGEN’s FA Score has 0 green FA rating(s), and RVTY’s FA Score reflects 2 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- RGEN’s FA Score: 0 green, 5 red.
- RVTY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 4 TA indicator(s) are bullish while RGEN’s TA Score has 4 bullish TA indicator(s), and RVTY’s TA Score reflects 4 bullish TA indicator(s).
- DHR’s TA Score: 4 bullish, 5 bearish.
- RGEN’s TA Score: 4 bullish, 4 bearish.
- RVTY’s TA Score: 4 bullish, 5 bearish.
Price Growth
DHR (@Medical Specialties) experienced а -2.29% price change this week, while RGEN (@Pharmaceuticals: Other) price change was -9.92% , and RVTY (@Medical Specialties) price fluctuated +1.53% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.15%. For the same industry, the average monthly price growth was -0.04%, and the average quarterly price growth was +7.58%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.40%. For the same industry, the average monthly price growth was -0.68%, and the average quarterly price growth was -3.63%.
Reported Earning Dates
DHR is expected to report earnings on Oct 27, 2026.
RGEN is expected to report earnings on Jul 28, 2026.
RVTY is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Medical Specialties (-0.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+1.40% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| DHR | RGEN | RVTY | |
| Capitalization | 138B | 7.38B | 12.1B |
| EBITDA | 7.08B | 176M | 773M |
| Gain YTD | -13.801 | -20.017 | 11.926 |
| P/E Ratio | 35.03 | 143.84 | 51.96 |
| Revenue | 24.8B | 763M | 2.9B |
| Total Cash | N/A | 785M | N/A |
| Total Debt | 18.5B | 688M | 3.35B |
DHR | RGEN | RVTY | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 69 | 70 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 83 Overvalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 80 | 90 | 89 | |
PRICE GROWTH RATING 1..100 | 56 | 57 | 45 | |
P/E GROWTH RATING 1..100 | 72 | 100 | 27 | |
SEASONALITY SCORE 1..100 | n/a | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (8) in the Medical Specialties industry is in the same range as RVTY (15) in the Medical Specialties industry, and is significantly better than the same rating for RGEN (83) in the Biotechnology industry. This means that DHR's stock grew similarly to RVTY’s and significantly faster than RGEN’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RVTY (100) in the Medical Specialties industry, and is in the same range as RGEN (100) in the Biotechnology industry. This means that DHR's stock grew similarly to RVTY’s and similarly to RGEN’s over the last 12 months.
DHR's SMR Rating (80) in the Medical Specialties industry is in the same range as RVTY (89) in the Medical Specialties industry, and is in the same range as RGEN (90) in the Biotechnology industry. This means that DHR's stock grew similarly to RVTY’s and similarly to RGEN’s over the last 12 months.
RVTY's Price Growth Rating (45) in the Medical Specialties industry is in the same range as DHR (56) in the Medical Specialties industry, and is in the same range as RGEN (57) in the Biotechnology industry. This means that RVTY's stock grew similarly to DHR’s and similarly to RGEN’s over the last 12 months.
RVTY's P/E Growth Rating (27) in the Medical Specialties industry is somewhat better than the same rating for DHR (72) in the Medical Specialties industry, and is significantly better than the same rating for RGEN (100) in the Biotechnology industry. This means that RVTY's stock grew somewhat faster than DHR’s and significantly faster than RGEN’s over the last 12 months.
| DHR | RGEN | RVTY | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 43% | 2 days ago 74% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 69% | 2 days ago 83% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 63% | 2 days ago 76% | 2 days ago 72% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 79% | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 80% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 53% | 2 days ago 81% | 2 days ago 62% |
| Advances ODDS (%) | 6 days ago 54% | 13 days ago 74% | 6 days ago 64% |
| Declines ODDS (%) | 8 days ago 61% | 2 days ago 81% | 2 days ago 67% |
| BollingerBands ODDS (%) | 2 days ago 64% | 2 days ago 82% | 2 days ago 74% |
| Aroon ODDS (%) | 2 days ago 57% | 2 days ago 76% | 2 days ago 64% |
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | +2.61% | ||
| TMO - DHR | 77% Closely correlated | -1.54% | ||
| A - DHR | 73% Closely correlated | -0.49% | ||
| RGEN - DHR | 68% Closely correlated | -0.68% | ||
| BIO - DHR | 64% Loosely correlated | +0.62% | ||
| BRKR - DHR | 58% Loosely correlated | -0.66% | ||
More | ||||